Biotech startups have not had an easy time in 2022. After record numbers of new biotech stock offerings in 2020 and 2021, a market downturn shut the door on IPOs for many young drugmakers, forcing their venture capital backers to adjust. While markets have steadied so far through the second half of 2022, the effects are still lingering as would-be investors keep their pencils sharpened.
Join us as we speak with industry experts to answer these questions, as well as discuss ever-present challenges like securing new funding, finding talent and managing the often messy process of developing new drugs.
Event Powered By: